BCL7B

Across TCGA pan-cancer cohorts, BCL7B RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of BCL7B’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where BCL7B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types BCL7B is over-expressed in tumor, although a few such as BLCA and THCA show the opposite, repressed pattern.

HNSC, LIHC, and KIRC are the cancer types where BCL7B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BCL7B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+0.826	<.001	12	view →
LIHC	Female	II,III,IV	+0.830	<.001	9	view →
KIRC	Female	All	+0.333	<.001	9	view →
BLCA	Male	All	−0.650	.006	8	view →
KIRP	All	All	+0.417	<.001	8	view →
THCA	All	All	−0.189	.001	6	view →
CHOL	Male	All	+1.366	<.001	5	view →
LUSC	All	II,III,IV	−0.457	<.001	5	view →
READ	Female	All	−0.493	.020	4	view →
LUAD	All	All	−0.277	<.001	3	view →
ESCA	All	All	+0.818	<.001	2	view →
KICH	All	All	−0.302	.014	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

BCL7B–HNSC

Open the HNSC breakdown →